No profile data available.
Goldenwell Biotech, Inc. (GWLL) is a healthcare company in the nutritional and natural health products industry, based in Solon, United States.
It reported revenue of $55 for fiscal year 2025, down 60.4% from fiscal year 2024, and net income of -$296,471. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0, down 100.0% from a year before. Its market capitalization was $68.28 million as of October 8, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 8, 2026.
Goldenwell Biotech, Inc. engages in the nutraceutical and dietary supplements business. It offers JI MAI, a bovine cardiac vascular active peptide; Double Proline AG, a 3D active collagen peptide drinkable cosmetic; Cartilage Peptide, a Type II collagen peptide; and Sugar Master, a dietary supplement.
Goldenwell Biotech reported $55 in revenue for fiscal year 2025, down 60.4% from $139 in fiscal year 2024. In Q2 2026 revenue was $0.
$68.28 million as of October 8, 2026.
Listed companies of a similar size in the same industry (nutritional and natural health products) include Nature's Sunshine Products, Inc. (NATR), Niagen Bioscience, Inc. (NAGE), LifeVantage Corporation (LFVN), Clene Inc. (CLNN).